Journey Medical Co. (NASDAQ:DERM) CEO Sells $74,674.05 in Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 14,905 shares of Journey Medical stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.01, for a total transaction of $74,674.05. Following the sale, the chief executive officer now directly owns 2,052,418 shares in the company, valued at approximately $10,282,614.18. The trade was a 0.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Claude Maraoui also recently made the following trade(s):

• On Tuesday, March 11th, Claude Maraoui sold 49,271 shares of Journey Medical stock. The shares were sold at an average price of $5.01, for a total transaction of $246,847.71.
• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Stock Up 3.1 %

DERM stock opened at $5.31 on Thursday. The firm has a market cap of $110.93 million, a PE ratio of -5.65 and a beta of 0.97. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. The firm’s 50 day moving average price is $4.65 and its 200-day moving average price is $5.09. Journey Medical Co. has a one year low of $2.85 and a one year high of $6.89.

Institutional Trading of Journey Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers raised its position in Journey Medical by 21.8% in the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares during the period. Nwam LLC purchased a new stake in Journey Medical in the third quarter valued at approximately $59,000. Kovitz Investment Group Partners LLC purchased a new stake in Journey Medical in the third quarter valued at approximately $66,000. Dimensional Fund Advisors LP purchased a new stake in Journey Medical in the fourth quarter valued at approximately $80,000. Finally, Citadel Advisors LLC purchased a new stake in Journey Medical in the fourth quarter valued at approximately $174,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.